Medicare Enrolled
Dr. Sridhar Beeram, MD
Hematology & Oncology · San Antonio, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Speaking/Promotional
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Beeram from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Beeram? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Beeram
Dr. Sridhar Beeram is a hematology & oncology in San Antonio, TX, with 19 years in practice. Based on federal Medicare data, Dr. Beeram performed 131,964 Medicare services across 4,663 unique beneficiaries.
Between the years covered by Open Payments, Dr. Beeram received a total of $51,121 from 70 pharmaceutical and/or device companies across 935 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Beeram is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice▲ Top 4% volume in TX$ $51,121 industry payments
Medicare Practice Summary
Medicare Utilization ↗131,964
Medicare services
Top 4% in TX for hematology & oncology
4,663
Unique beneficiaries
$14
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~6,945 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Darbepoetin injection (Aranesp) for anemia | 31,295 | $2 | $20 |
| Pembrolizumab injection (Keytruda) | 21,700 | $43 | $137 |
| Iron infusion (Feraheme) | 13,770 | $0 | $5 |
| Anti-nausea injection (fosaprepitant) | 11,850 | $0 | $5 |
| Azacitidine chemotherapy injection | 8,250 | $0 | $13 |
| Immune globulin infusion (Octagam) | 7,590 | $33 | $233 |
| Denosumab injection (Prolia/Xgeva) | 6,240 | $18 | $66 |
| Contrast dye for imaging (iodine-based) | 4,985 | $0 | $3 |
| Paclitaxel chemotherapy injection | 4,256 | $0 | $8 |
| Injection, docetaxel, 1 mg | 2,632 | $0 | $66 |
| Blood draw (venipuncture) | 1,609 | $8 | $20 |
| Complete blood count (CBC) with differential | 1,555 | $8 | $36 |
| Comprehensive metabolic blood panel | 1,552 | $10 | $64 |
| Dexamethasone injection (steroid) | 1,444 | $0 | $1 |
| Lactate dehydrogenase (enzyme) level | 1,415 | $6 | $31 |
| Office visit, established patient (30-39 min) | 1,364 | $90 | $368 |
| Injection, granisetron hydrochloride, 100 mcg | 1,320 | $0 | $24 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,080 | $1 | $114 |
| Injection, leucovorin calcium, per 50 mg | 607 | $3 | $25 |
| Injection, fluorouracil, 500 mg | 521 | $2 | $13 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 464 | $22 | $157 |
| Administration of chemotherapy into vein, 1 hour or less | 448 | $97 | $707 |
| Flow cytometry, additional marker | 395 | $17 | $180 |
| Immunoglobulin level test | 378 | $9 | $56 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 370 | $3 | $373 |
| Injection, zoledronic acid, 1 mg | 368 | $7 | $431 |
| Drug injection, under skin or into muscle | 261 | $11 | $96 |
| Hospital follow-up visit, moderate complexity | 259 | $60 | $247 |
| Measurement of immunoglobulin light chains | 228 | $17 | $60 |
| Ferritin level test (iron stores) | 221 | $13 | $60 |
| Iron level test | 209 | $6 | $27 |
| Iron binding capacity test | 209 | $9 | $35 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 201 | $47 | $313 |
| Carcinoembryonic antigen (cea) protein level | 185 | $18 | $99 |
| Reticulated (young) platelet measurement | 184 | $34 | $143 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 178 | $15 | $100 |
| Injection, carboplatin, 50 mg | 164 | $2 | $300 |
| Injection of additional new drug or substance into vein | 155 | $12 | $108 |
| Injection, diphenhydramine hcl, up to 50 mg | 155 | $1 | $7 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 132 | $55 | $211 |
| Office visit, established patient (20-29 min) | 129 | $61 | $250 |
| Administration of additional new drug or substance into vein, 1 hour or less | 122 | $48 | $344 |
| Coagulation function measurement, d-dimer; quantitative | 103 | $10 | $129 |
| Microscopic examination for white blood cells with manual cell count | 102 | $4 | $22 |
| Complete blood count (CBC), automated | 102 | $6 | $34 |
| Administration of chemotherapy into vein, each additional hour | 101 | $21 | $161 |
| Red blood count automated, with additional calculations | 98 | $5 | $26 |
| Sed rate test (inflammation marker) | 94 | $3 | $36 |
| New patient office visit, complex (60-74 min) | 92 | $158 | $709 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | 79 | $20 | $128 |
| PSA test (prostate cancer screening) | 74 | $17 | $94 |
| Initial hospital admission, high complexity | 71 | $133 | $694 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 54 | $122 | $500 |
| Administration of additional new drug or substance into vein using push technique | 53 | $41 | $289 |
| Ct scan of chest with contrast | 47 | $39 | $821 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 47 | $15 | $94 |
| CT scan of abdomen and pelvis with contrast | 40 | $159 | $1,067 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 38 | $1 | $19 |
| Unclassified drugs | 36 | $1 | $8 |
| Prothrombin time test (blood clotting) | 31 | $4 | $30 |
| Office visit, established patient, complex (40-54 min) | 29 | $133 | $496 |
| Beta-2 microglobulin (protein) level | 24 | $15 | $96 |
| Drawing of blood for a medical problem | 23 | $67 | $264 |
| Infusion into a vein for hydration, each additional hour | 18 | $10 | $75 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 17 | $1,109 | $4,802 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 17 | $90 | $657 |
| Urinalysis with microscopic exam | 16 | $3 | $28 |
| Flow cytometry technique for dna or cell analysis, first marker | 16 | $53 | $298 |
| Irrigation of implanted venous access drug delivery device | 16 | $16 | $114 |
| Injection, hydrocortisone sodium succinate, up to 100 mg | 15 | $14 | $35 |
| CT scan of chest, without contrast | 14 | $31 | $686 |
| Ct scan of abdomen and pelvis without contrast | 12 | $70 | $560 |
| Vitamin B-12 level test | 12 | $15 | $76 |
| Folic acid level test | 12 | $14 | $73 |
| Initial hospital admission, moderate complexity | 11 | $100 | $470 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
16.9% high complexity
74.6% medium
8.4% routine
Industry Payment Transparency
Open Payments through 2024 ↗$51,121
Total received (2018-2024)
Avg $7,303/year across 7 years
Top 12% in TX for hematology & oncology
70
Companies
935
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$32,838 (64.2%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$15,705 (30.7%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$2,578 (5.0%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$1,797
2023$1,426
2022$5,942
2021$8,305
2020$4,007
2019$19,307
2018$10,336
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
PFIZER INC.
$25,819
E.R. Squibb & Sons, L.L.C.
$5,170
Alexion Pharmaceuticals, Inc.
$2,364
AstraZeneca Pharmaceuticals LP
$2,252
Celgene Corporation
$2,153
Novartis Pharmaceuticals Corporation
$1,053
Amgen Inc.
$1,028
Janssen Biotech, Inc.
$960
Genentech USA, Inc.
$806
Takeda Pharmaceuticals U.S.A., Inc.
$631
Astellas Pharma US Inc
$630
Incyte Corporation
$603
Eisai Inc.
$551
GENZYME CORPORATION
$517
Merck Sharp & Dohme Corporation
$510
Bayer HealthCare Pharmaceuticals Inc.
$396
Janssen Pharmaceuticals, Inc
$386
AbbVie, Inc.
$366
Bayer Healthcare Pharmaceuticals Inc.
$331
Regeneron Healthcare Solutions, Inc.
$324
Seattle Genetics, Inc.
$301
Lilly USA, LLC
$277
Rigel Pharmaceuticals, Inc.
$218
Gilead Sciences, Inc.
$176
Boehringer Ingelheim Pharmaceuticals, Inc.
$161
EMD Serono, Inc.
$157
EISAI INC.
$156
Karyopharm Therapeutics Inc.
$153
Nevro Corp.
$150
JAZZ PHARMACEUTICALS INC.
$145
GlaxoSmithKline, LLC.
$144
Exelixis Inc.
$143
Tempus AI, Inc
$138
Puma Biotechnology, Inc.
$127
Genmab U.S., Inc.
$125
Novocure Inc.
$124
Agios Pharmaceuticals, Inc.
$122
Myriad Genetic Laboratories, Inc.
$117
TESARO, Inc.
$110
Merck Sharp & Dohme LLC
$101
Clovis Oncology, Inc.
$99
Verastem, Inc.
$89
Ipsen Biopharmaceuticals, Inc
$87
Daiichi Sankyo Inc.
$87
Jazz Pharmaceuticals Inc.
$80
Taiho Oncology, Inc.
$55
TerSera Therapeutics LLC
$49
TOLMAR Pharmaceuticals, Inc.
$45
Octapharma USA, Inc.
$42
Foundation Medicine, Inc.
$39
Spectrum Pharmaceuticals Inc.
$36
AMAG Pharmaceuticals, Inc.
$33
Apellis Pharmaceuticals, Inc.
$30
Medtronic USA, Inc.
$30
Alnylam Pharmaceuticals Inc.
$29
Lexicon Pharmaceuticals, Inc.
$29
Pharmacyclics LLC, An AbbVie Company
$28
Kite Pharma, Inc.
$25
ARRAY BIOPHARMA INC
$25
Secura Bio, Inc.
$25
Teva Pharmaceuticals USA, Inc.
$24
Otsuka America Pharmaceutical, Inc.
$24
Helsinn Therapeutics (U.S.), Inc.
$23
SANOFI-AVENTIS U.S. LLC
$20
INSYS Therapeutics Inc
$17
Dendreon Pharmaceuticals LLC
$13
Advanced Accelerator Applications
$12
Array BioPharma Inc.
$12
Seagen Inc.
$12
Kyowa Kirin, Inc.
$11
Top 3 companies account for 65.2% of total payments
Associated products mentioned in payments ›
ABILIFY · ADCETRIS · AFINITOR · AKYNZEO · ALIMTA · AREXVY · Abraxane · Alecensa · Aliqopa · Avastin · BALVERSA · BAVENCIO · BENDEKA · BOSULIF · BRAFTOVI · Balversa · Bavencio · Blincyto · Braftovi · CABLIVI · CALQUENCE · CHANTIX · COPIKTRA · CYRAMZA · Cabometyx · Copiktra · DARZALEX · ELIGARD · ELIQUIS · ELITEK · EMEND · EMPLICITI · ENHERTU · ERBITUX · ERLEADA · EXKIVITY · Empaveli · Enhertu · Epkinly · Erleada · FARESTON · FARXIGA · FARYDAK · FERAHEME · FOUNDATIONONE · FRUZAQLA · Folotyn · GAZYVA · GILOTRIF · GIVLAARI · HEMLIBRA · Halaven · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · Imbruvica · Inrebic · JADENU · JAKAFI · JEVTANA · KEYTRUDA · KISQALI · Kyprolis · LIBTAYO · LUTATHERA · LYNPARZA · Lenvima · Lonsurf · Lupron · Lupron Depot · Lutathera · MEKINIST · MVASI · MYLOTARG · MYRISK · NERLYNX · NINLARO · Nerlynx · Neulasta · Nexavar · Nplate · Nubeqa · ONUREG · OPDIVO · OPDUALAG · OPTUNE LUA (NOVOTTF-200T) · OSTEOCOOL RF ABLATION · PADCEV · PANZYGA · PIQRAY · PROMACTA · PROVENGE · Padcev · Perjeta · Pomalyst · REBLOZYL · RYBREVANT · RYDAPT · Revlimid · Rubraca · SANDOSTATIN · SOLIRIS · SOMATULINE DEPOT · SPRYCEL · SUTENT · SYNDROS · Senza · Stivarga · TAGRISSO · TALZENNA · TASIGNA · TECENTRIQ · TIBSOVO · TUMOR LYSIS SYNDROME - DISEASE · Tavalisse · Trodelvy · ULTOMIRIS · VENCLEXTA · VOTRIENT · VYNDAQEL · VYXEOS · Vectibix · Venclexta · Vitrakvi · Vyloy · WILATE · XALKORI · XARELTO · XGEVA · XOSPATA · XPOVIO · XTANDI · Xermelo · Xofigo · Yescarta · ZEJULA · ZEPZELCA · ZOLADEX
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (64%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in hematology & oncology and does not inherently indicate bias, but patients may wish to be aware.
Equivalent to $39 per 100 Medicare services performed
Geographic Context
Hematology & Oncologys within 10 mi
56
Per 100K population
2.7
County median income
$70,571
Nearest hospital
SAN ANTONIO BEHAVIORAL HEALTHCARE HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Beeram is a mixed practice specialist, with above-average Medicare volume (top 4% in TX), and high industry engagement (speaking/promotional, top 12%), with 19 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Beeram experienced with darbepoetin injection (aranesp) for anemia?
Based on Medicare claims data, Dr. Beeram performed 31,295 darbepoetin injection (aranesp) for anemia services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Beeram receive payments from pharmaceutical companies?
Yes. Dr. Beeram received a total of $51,121 from 70 companies across 935 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Beeram's costs compare to other hematology & oncologys in San Antonio?
Dr. Beeram's average Medicare payment per service is $14. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Beeram) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncologys in San Antonio
Browse hematology & oncologys in San Antonio ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncologys in TX
Hematology & Oncologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncologys in TX
Which TX hematology & oncologys receive the most from drug and device companies.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC..
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C..
By company
Alexion Pharmaceuticals, Inc. Payments to Doctors
See all physicians who received payments from Alexion Pharmaceuticals, Inc..
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology